Literature DB >> 2522289

Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.

R J Hudson1, R G Bergstrom, I R Thomson, M A Sabourin, M Rosenbloom, L Strunin.   

Abstract

The authors determined the pharmacokinetics of sufentanil, 12.5 micrograms.kg-1 iv in patients undergoing elective abdominal aortic surgery. The mean age (+/- SD) of the ten patients was 68.4 +/- 7.9 yr; their mean weight was 74.4 +/- 19.1 kg. Six patients underwent aortobifemoral grafting and four had abdominal aortic aneurysm repair. Serum sufentanil concentrations were determined in samples drawn at increasing intervals over a 24-h period. A three-compartment pharmacokinetic model was fit to the concentration versus time data. Total drug clearance was 15.0 +/- 3.2 ml.min-1.kg-1. The volume of distribution at steady-state (Vdss) was 8.7 +/- 4.5 l.kg-1. The elimination half-time were positively correlated with patient age. There were no significant correlations between the pharmacokinetic variables and the duration of aortic cross-clamping, the duration of surgery, or the rate or total volume of iv fluids given intraoperatively. In general surgical patients, the mean elimination half-time of sufentanil has been reported to be 2.7 h. When sufentanil is used in large doses as the primary anesthetic agent for patients undergoing abdominal aortic surgery, the long elimination half-time observed implies that recovery will take much longer than would have been anticipated from previously published pharmacokinetic data.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522289     DOI: 10.1097/00000542-198903000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  [Brain death diagnosis after sedation with propofol or sufentanil. Recommendations for the usage of toxicological analytics].

Authors:  U Walter; U Brüderlein; M Gloger; S Mann; U Walther
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-09-26       Impact factor: 0.840

3.  Apnoea and unconsciousness after apparent recovery from alfentanil-supplemented anaesthesia.

Authors:  R J Hudson
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

Review 4.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

5.  Cardiovascular response of a continuous variable rate alfentanil infusion for abdominal aortic surgery.

Authors:  D R Miller; R J Martineau; D Ewing; K A Hull; J L Wellington; A G Bouchard
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

6.  Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdominal surgery.

Authors:  R H Taverne; T I Ionescu; S T Nuyten
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 7.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery.

Authors:  R J Hudson; I R Thomson; P M Burgess; M Rosenbloom
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

9.  Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.

Authors:  J Scholz; H Bause; M Schulz; U Klotz; D R Krishna; S Pohl; J Schulte am Esch
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

10.  Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients.

Authors:  Frédéric Ethuin; Said Boudaoud; Isabelle Leblanc; Christian Troje; Olivier Marie; Jean-Claude Levron; Jean-Pierre Le Moing; Patrice Assoune; Benoit Eurin; Laurent Jacob
Journal:  Intensive Care Med       Date:  2003-08-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.